MENLO PARK, Calif., April 30, 2019 /PRNewswire/ — Ablacon, Inc., a Wheat Ridge, CO-based company developing an advanced mapping system to guide the treatment of atrial fibrillation (AFib), today announced the closing of a $21.5 million Series A financing round led by Ajax Health. Ablacon’s novel algorithm uses artificial intelligence (AI) to analyze and visualize the flow of action potentials, or Electrographic Flow, within the heart in order to identify sources and drivers of AFib, the most common cardiac arrhythmia worldwide. The map of the Electrographic Flow can help to guide physicians in targeted catheter ablation therapy. The company will use the Series A funding to advance its technology pipeline and finance clinical trials.
Posts
Ablamap® System and Ablacath is FDA 510(k) cleared for use in the United States.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use for information on Indications, Contraindications, Warnings, Precautions and Adverse events.
Copyright © 2023 Ablacon, Inc.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use for information on Indications, Contraindications, Warnings, Precautions and Adverse events.
Copyright © 2023 Ablacon, Inc.